InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: Protector post# 267745

Thursday, 05/16/2019 7:39:27 AM

Thursday, May 16, 2019 7:39:27 AM

Post# of 345952

BMY did the opposite and has given PD-L1 up, probably due to the Medarex story. That could become a regrettable decision in the future.



PS Targeting and IO Combos

I believe you will be correct in regards to Microsoft because Adaptive Biotechnologies to Roche with help from AI and biomarkers required PS Targeting data to build the AI data

I look forward to hearing about Oncologie nondisclosed partners

Royalties and Milestones where the CDMO is all based upon PS Targeting and more hidden behind the John Springs Stafford show
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News